Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Functional and structural brain imaging in Alzheimer's Disease: Towards a biomarker of treatment response and decline

EF 2008-09

Résumé
Alzheimer's Disease (AD) is the most common cause of dementia. Progress towards new treatments for AD has led to an effort to find biological markers of the disease, which may aid in diagnosis, tracking, and predicting response to drug treatment. Functional brain imaging, where measures of brain activity are recorded while performing a task, has been used for this important goal, with promising results. There is evidence that patients show greater activity than healthy participants in some brain regions, which correlates with better cognitive status. However some studies fail to find these changes, and the interacting effects of brain degeneration, medication and task difficulty on these findings are unknown. Our study aims to identify the impact of structural degeneration and medication status on cortical activation, using a simple task that patients can easily perform while being scanned with functional MRI (fMRI). We focus on an area important to face perception, the fusiform face area (FFA), which is implicated in these activity changes, is structurally affected, and changes in activation following treatment. We will record brain activity while 15 patients and 15 healthy older adults view faces, and measure grey and white matter integrity with structural MRI and diffusion tensor imaging. We will scan patients once before beginning drug treatment with a cholinesterase inhibitor (ChEI) and once after 6 months of treatment. We hypothesize that patients will show significant differences in FFA activity compared to healthy controls, the degree of which will be related to structural integrity. Further, we predict that drug treatment will increase FFA activity, and the degree of this increase will predict clinical response to the drug. This study will contribute to our understanding of changes in brain function noted in AD patients, and contribute to a reliable biomarker of disease severity and response to drug treatment.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
184558
Name
Schwindt Graeme C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Functional and structural brain imaging in Alzheimer's Disease: Towards a biomarker of treatment response and decline
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Diffusion Tensor Imaging; Functional Magnetic Resonance Imaging
Abstract
Alzheimer's Disease (AD) is the most common cause of dementia. Progress towards new treatments for AD has led to an effort to find biological markers of the disease, which may aid in diagnosis, tracking, and predicting response to drug treatment. Functional brain imaging, where measures of brain activity are recorded while performing a task, has been used for this important goal, with promising results. There is evidence that patients show greater activity than healthy participants in some brain regions, which correlates with better cognitive status. However some studies fail to find these changes, and the interacting effects of brain degeneration, medication and task difficulty on these findings are unknown. Our study aims to identify the impact of structural degeneration and medication status on cortical activation, using a simple task that patients can easily perform while being scanned with functional MRI (fMRI). We focus on an area important to face perception, the fusiform face area (FFA), which is implicated in these activity changes, is structurally affected, and changes in activation following treatment. We will record brain activity while 15 patients and 15 healthy older adults view faces, and measure grey and white matter integrity with structural MRI and diffusion tensor imaging. We will scan patients once before beginning drug treatment with a cholinesterase inhibitor (ChEI) and once after 6 months of treatment. We hypothesize that patients will show significant differences in FFA activity compared to healthy controls, the degree of which will be related to structural integrity. Further, we predict that drug treatment will increase FFA activity, and the degree of this increase will predict clinical response to the drug. This study will contribute to our understanding of changes in brain function noted in AD patients, and contribute to a reliable biomarker of disease severity and response to drug treatment.
Competitiondate
200811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Schwindt, Graeme C
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~